Search for other papers by Ana Carolina de Jesus Paniza in
Google Scholar
PubMed
Search for other papers by Thais Biude Mendes in
Google Scholar
PubMed
Search for other papers by Matheus Duarte Borges Viana in
Google Scholar
PubMed
Search for other papers by Débora Mota Dias Thomaz in
Google Scholar
PubMed
Search for other papers by Paula B O Chiappini in
Google Scholar
PubMed
Search for other papers by Gabriel A Colozza-Gama in
Google Scholar
PubMed
Search for other papers by Susan Chow Lindsey in
Google Scholar
PubMed
Search for other papers by Marcos Brasilino de Carvalho in
Google Scholar
PubMed
Search for other papers by Venâncio Avancini Ferreira Alves in
Google Scholar
PubMed
Search for other papers by Otavio Curioni in
Google Scholar
PubMed
Department of Microbiology, Instituto de Ciências Biomédicas, Universidade de São Paulo, São Paulo, Brazil
Search for other papers by André Uchimura Bastos in
Google Scholar
PubMed
Search for other papers by Janete Maria Cerutti in
Google Scholar
PubMed
already proposed less aggressive treatment performed for benign lesions. To date, this evaluation cannot be replaced by preoperative molecular tests as the mutational profiling of this indolent category is still not completely understood, but the molecular
Search for other papers by Dario de Biase in
Google Scholar
PubMed
Search for other papers by Federica Torricelli in
Google Scholar
PubMed
Search for other papers by Moira Ragazzi in
Google Scholar
PubMed
Search for other papers by Benedetta Donati in
Google Scholar
PubMed
Search for other papers by Elisabetta Kuhn in
Google Scholar
PubMed
Search for other papers by Michela Visani in
Google Scholar
PubMed
Search for other papers by Giorgia Acquaviva in
Google Scholar
PubMed
Search for other papers by Annalisa Pession in
Google Scholar
PubMed
Search for other papers by Giovanni Tallini in
Google Scholar
PubMed
Search for other papers by Simonetta Piana in
Google Scholar
PubMed
Search for other papers by Alessia Ciarrocchi in
Google Scholar
PubMed
follicular thyroid cancer: current status and future directions . Molecular and Cellular Endocrinology 2010 322 8 – 28 . ( https://doi.org/10.1016/j.mce.2010.01.007 ) 6 Cappola AR Mandel SJ. Molecular testing in thyroid cancer: BRAF mutation status
Search for other papers by Anello Marcello Poma in
Google Scholar
PubMed
Search for other papers by Riccardo Giannini in
Google Scholar
PubMed
Search for other papers by Paolo Piaggi in
Google Scholar
PubMed
Search for other papers by Clara Ugolini in
Google Scholar
PubMed
Search for other papers by Gabriele Materazzi in
Google Scholar
PubMed
Search for other papers by Paolo Miccoli in
Google Scholar
PubMed
Search for other papers by Paolo Vitti in
Google Scholar
PubMed
Search for other papers by Fulvio Basolo in
Google Scholar
PubMed
-0288 20668010 25 Nikiforov YE Steward DL Robinson-Smith TM Haugen BR Klopper JP Zhu Z Fagin JA Falciglia M Weber K Nikiforova MN. Molecular testing for mutations in improving the fine-needle aspiration diagnosis of
Search for other papers by Luigi Laino in
Google Scholar
PubMed
Search for other papers by Silvia Majore in
Google Scholar
PubMed
Search for other papers by Nicoletta Preziosi in
Google Scholar
PubMed
Search for other papers by Barbara Grammatico in
Google Scholar
PubMed
Search for other papers by Carmelilia De Bernardo in
Google Scholar
PubMed
Search for other papers by Salvatore Scommegna in
Google Scholar
PubMed
Search for other papers by Anna Maria Rapone in
Google Scholar
PubMed
Search for other papers by Giacinto Marrocco in
Google Scholar
PubMed
Search for other papers by Irene Bottillo in
Google Scholar
PubMed
Search for other papers by Paola Grammatico in
Google Scholar
PubMed
based on clinical and cytogenetic findings was revealed to be an important starting point to carry out the further appropriate molecular testing, specific for each DSD subgroup. Out of 88 patients, 7 (8%) were classified as 46,XX testicular DSD and
Search for other papers by Ishita Gupta in
Google Scholar
PubMed
Search for other papers by Allal Ouhtit in
Google Scholar
PubMed
Search for other papers by Adil Al-Ajmi in
Google Scholar
PubMed
Search for other papers by Syed Gauhar A Rizvi in
Google Scholar
PubMed
Search for other papers by Hamad Al-Riyami in
Google Scholar
PubMed
Search for other papers by Marwa Al-Riyami in
Google Scholar
PubMed
Search for other papers by Yahya Tamimi in
Google Scholar
PubMed
and/or carriers of benign tumors from January 2012 to April 2014 underwent biopsy and breast cancer surgery. Breast cancer was confirmed by biopsy reports as well as pathologically by molecular tests including estrogen receptor (ER), progesterone
European Institute for Molecular Imaging (EIMI), University of Münster, Münster, Germany
Search for other papers by Daniel Alexander Hescheler in
Google Scholar
PubMed
Search for other papers by Milan Janis Michael Hartmann in
Google Scholar
PubMed
Search for other papers by Burkhard Riemann in
Google Scholar
PubMed
Search for other papers by Maximilian Michel in
Google Scholar
PubMed
Search for other papers by Christiane Josephine Bruns in
Google Scholar
PubMed
Search for other papers by Hakan Alakus in
Google Scholar
PubMed
Search for other papers by Costanza Chiapponi in
Google Scholar
PubMed
the increasing role of molecular testing in clinical routine is evolving ( 5 ). The Food and Drug Administration (FDA) approval of the combination BRAF/MEK inhibitor therapy for the management of BRAF V600E-positive ATC in 2018 was a major first step
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
Search for other papers by Xu-Feng Chen in
Google Scholar
PubMed
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
Search for other papers by Cong He in
Google Scholar
PubMed
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
Search for other papers by Peng-Cheng Yu in
Google Scholar
PubMed
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
Search for other papers by Wei-Dong Ye in
Google Scholar
PubMed
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
Search for other papers by Pei-Zheng Han in
Google Scholar
PubMed
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
Search for other papers by Jia-Qian Hu in
Google Scholar
PubMed
Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, People’s Republic of China
Search for other papers by Yu-Long Wang in
Google Scholar
PubMed
://doi.org/10.1210/jc.2012-2104 ) 12 Cappola AR & Mandel SJ . Molecular testing in thyroid cancer: BRAF mutation status and mortality . JAMA 2013 309 1529 – 1530 . ( https://doi.org/10.1001/jama.2013.3620 ) 13 Xing M Alzahrani AS Carson KA